Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs Bolus Terlipressin in ACLF Variceal Bleed
NCT06815770Phase 3Not yet recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Feb 2025
- Primary completion
- Feb 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of terlipressin in esophageal variceal bleeding (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Hepatic Venous Pressure Gradient reduction > 10%. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
terlipressin
03
Conditions
esophageal variceal bleeding
Beyond the preview
Go deeper on NCT06815770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06815770.